Last reviewed · How we verify

CX501 — Competitive Intelligence Brief

CX501 (CX501) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Muscular Dystrophy.

phase 2 dystrophin gene Muscular Dystrophy Small molecule Live · refreshed every 30 min

Target snapshot

CX501 (CX501) — Tigenix S.A.U.. CX501 is a gene therapy that aims to increase the production of dystrophin in patients with Duchenne muscular dystrophy.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
CX501 TARGET CX501 Tigenix S.A.U. phase 2 dystrophin gene
SRP-4045 SRP-4045 Sarepta Therapeutics, Inc. phase 3 Gene therapy Dystrophin gene
SGT-003 SGT-003 Solid Biosciences Inc. phase 3 Gene therapy Dystrophin gene

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CX501 — Competitive Intelligence Brief. https://druglandscape.com/ci/cx501. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: